UK Community Advisory Board (UK-CAB)

CAB 80: Long-acting agents, CROI and BHIVA feedback

Date: 23 April 2022
Venue:   Gorge House Trust, 75-77 Ardwick Green N, Manchester M12 6FX


Chair: Jo Josh
09.30-10.00 Arrival, tea and refreshments, expenses
09:50- 10.00 Welcome and introductions
UK-CAB updates
10:00-11:00 Long-acting agents (injectables) – setting the scene for longer-acting drugs and how they work? – Joshua Wharton – George House Trust; Alex Sparrowhawk – UK-CAB Chair
11.00-11.15 BREAK
11.15-12.15 CROI feedback – Simon Collins
12.15-12.45 Migrants and HIV; Ukraine and current policy – George Westwood, NAT
12.45-13.45 Lunch (will be delivered at venue)
Chair: Alex Sparrowhawk
13.45-14.45 BHIVA Conference feedback by members
Roger Pebody
Rebecca Walker
Jo Josh
14.45-15:30 UK-CAB online training programme – Ben Cromarty
15:30 -16.00 Members Updates
Meeting reflection
Any other business
16.00 Meeting close

Slides and report from this meeting

Injectables – What is the demand and how do they fit into current practice?
CROI 2022 feedback
Migrants and HIV
BHIVA spring conference feedback
UK-CAB Online Training Programme
BHIVA Guidelines writing groups
Induction to NICE for patient organisations
Meeting report

Background reading

HIV i-Base reports from CROI 2022:

• Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
 Injectable CAB/RPV-LA: phase 3b ATLAS-2M results at three years
• Lenacapavir: 6-monthly dosing in treatment-experienced participants and as PrEP in macaques
• Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
• Islatravir studies for HIV treatment and PrEP

• Fourth potential stem cell HIV cure – in a US woman using donor cord cells
• Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
• Targeting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case
• Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
• No impact of high-dose vitamin D3 on reducing the HIV viral reservoir

• Risk factors for NAFLD and proteinuria in HIV positive people on ART
• ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
• Telomere shortening associated with TAF but not TDF in CHARTER study

• CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
• Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study


  • Since 2011, i-Base provide admin support to the UK-CAB. Other costs are covered by grants to the UK-CAB. This includes support from drug companies for meetings.
  • Training courses are funded by specific grants, including from the Lottery Fund.
  • From 2008-2011 the CAB was supported by the Monument Trust. This allowed us to employ a part-time administrator.
  • From 2002 to 2008, running costs for the UK-CAB were supported by i-Base. Drug companies funding meeting costs.

We have always asked HIV drug companies to support the direct costs for UK-CAB meetings.

This covers travel and accommodation for members coming from out of London. It also covers the cost of catering. This industry funding helps support the CAB as a national project. A list of supporting companies since the UK-CAB was established in 2002 and from the most recent years is included below. 3

The UK-CAB membership and Steering Group decides the content for all meetings.

Meetings with a drug company covers their current products and future research. The decision for which companies to invite and the agenda for these meetings is made by the UK-CAB.

We also ask other researchers to involve the UK-CAB in planning studies and ongoing research. We ask that community involvement in research be included in the budget of grant proposals so that some of the CAB work can be supported in this way by independent research.